LEVELS OF SYSTEMIC INFLAMMATORY RESPONSE MARKERS IN PATIENTS WITH PULMONARY HYPERTENSION AND COPD
Introduction. The prevalence of COPD worldwide is about 7.6 %, and it is one of the main causes of morbidity and mortality in today society. Today, much information has been obtained about the pathogenetic mechanisms of COPD development. However, more and more studies have recently shown that COPD p...
Main Authors: | I. M. Fushtey, K. L. Nikolaieva, E. V. Sid’ |
---|---|
Format: | Article |
Language: | English |
Published: |
Sumy State University
2020-03-01
|
Series: | Східноукраїнський медичний журнал |
Subjects: | |
Online Access: | https://eumj.med.sumdu.edu.ua/index.php/journal/article/view/74 |
Similar Items
-
Should We Change the Target of Therapy in Pulmonary Hypertension?
by: Panagiotis Karyofyllis, et al.
Published: (2023-05-01) -
Pulmonary Hypertension in COPD: A Case Study and Review of the Literature
by: Steven J. Cassady, et al.
Published: (2019-08-01) -
Safety and efficacy of balloon pulmonary angioplasty for technically operable chronic thromboembolic pulmonary hypertension
by: Jinzhi Wang, et al.
Published: (2024-01-01) -
TNF-α and IL-8 levels are positively correlated with hypobaric hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats
by: Shi Haixia, et al.
Published: (2023-07-01) -
Usefulness of pulmonary artery diameter in diagnosing pulmonary hypertension in patients admitted to tuberculosis intensive care unit
by: Armin Nowroozpoor, et al.
Published: (2016-01-01)